Necrobiosis lipoidica diabeticorum (NLD), commonly referred to as jelly diabetes, is a chronic, granulomatous skin condition that predominantly affects individuals with diabetes mellitus. Although it is uncommon, its distinctive clinical presentation can be confused with other dermatoses. Accurate differentiation is critical because NLD carries a risk of ulceration and requires specific management strategies aimed at both the cutaneous manifestations and the underlying glycemic control. This article provides a comprehensive overview of NLD, emphasizing how to distinguish it from other skin conditions that mimic its appearance, and offers guidance on diagnosis and treatment.

What Is Jelly Diabetes (Necrobiosis Lipoidica Diabeticorum)?

Necrobiosis lipoidica diabeticorum is a rare, idiopathic, inflammatory skin disease that was first described in 1929. It is characterized by sharply demarcated, shiny, yellowish-brown plaques that typically develop on the pretibial area (shins). The term "jelly diabetes" derives from the waxy, almost translucent quality of the plaques, which resembles jelly. The condition is strongly associated with diabetes, but about 10–30% of cases occur in individuals without diabetes or with impaired glucose tolerance. Among those with diabetes, NLD is more common in type 1 diabetes and tends to appear after many years of poor glycemic control. The overall prevalence in diabetic populations is estimated at 0.3–1.6%.

Pathophysiology and Contributing Factors

The exact cause of NLD remains unclear, but several mechanisms have been proposed. Microangiopathy, a hallmark of diabetic complications, plays a central role. Thickening of the basement membrane and endothelial damage in small blood vessels lead to reduced perfusion and tissue hypoxia. This triggers an inflammatory reaction with collagen degeneration (necrobiosis), lipid deposition, and granuloma formation. Immune-mediated factors, such as deposition of immunoglobulins and complement in blood vessel walls, suggest an autoimmune component. Additionally, altered collagen metabolism and increased oxidative stress contribute to the structural changes seen in the dermis.

Clinical Features of Jelly Diabetes

The classic presentation of NLD is as multiple, symmetric, well-circumscribed plaques on the anterior lower legs. Less commonly, the arms, face, scalp, or trunk may be involved. The key features include:

  • Appearance: Plaques are smooth, waxy, and shiny with a yellowish-brown or violaceous hue. The border may be raised and erythematous (active border), while the center becomes atrophic and slightly depressed.
  • Surface: Telangiectasias (visible small blood vessels) are often present on the surface. The skin may feel firm and indurated.
  • Size and progression: Lesions slowly enlarge over months to years. Spontaneous resolution is rare; most persist indefinitely.
  • Ulceration: Up to 30–35% of cases develop ulceration, which is painful, slow to heal, and prone to infection. Ulcers typically arise in the atrophic center following minor trauma.
  • Sensation: The plaques are usually asymptomatic or only mildly pruritic. However, ulceration causes significant pain.

Variants and Atypical Presentations

Some patients present with solitary, giant, or anetoderma-like lesions (loose, wrinkled skin). In dark skin, the color may appear hyperpigmented rather than yellow. A rare generalized form with widespread plaques has been reported. These variants can increase diagnostic difficulty.

Differentiating Jelly Diabetes from Other Skin Conditions

Several dermatologic conditions share overlapping features with NLD, especially on the lower legs. A systematic approach focusing on morphology, location, symptoms, and associated systemic findings is essential.

Comparison with Eczema (Dermatitis)

Eczema, particularly stasis dermatitis or neurodermatitis, can present as erythematous, scaly, and pruritic patches on the shins. However, eczema lacks the waxy, yellowish hue and the pronounced telangiectasias of NLD. Eczema is intensely itchy and shows lichenification (thickened skin from scratching). The patches are poorly defined and often accompanied by edema or varicose veins in stasis dermatitis. In contrast, NLD is typically nonpruritic and has a distinct, firm border. A skin biopsy easily distinguishes the two: eczema shows spongiosis and acanthosis, while NLD reveals palisading granulomas with collagen degeneration.

Comparison with Psoriasis

Plaque psoriasis on the lower legs can be confused with NLD when it appears as well-demarcated, erythematous plaques. However, psoriasis has a characteristic silvery, micaceous scale that is absent in NLD. Psoriatic plaques are very pruritic and often involve the elbows, knees, scalp, and nails. Koebner phenomenon (lesions developing at sites of trauma) is common. NLD plaques are smooth, non-scaling, and rarely pruritic; they slowly progress without the rapid turnover of epidermal cells seen in psoriasis. Histology of psoriasis shows parakeratosis, Munro microabscesses, and elongated rete ridges—quite different from the granulomatous pattern of NLD.

Comparison with Venous Stasis Dermatitis and Ulcers

Chronic venous insufficiency leads to stasis dermatitis characterized by erythema, scaling, hyperpigmentation (hemosiderin deposition), and edema of the lower legs. Ulceration typically occurs over the medial malleolus and is preceded by lipodermatosclerosis. While NLD ulcers are located on the anterior shin and arise within a yellowish plaque, venous ulcers are shallow, irregular, and surrounded by brownish discoloration and signs of venous hypertension (varicose veins, pitting edema). Doppler ultrasound reveals venous reflux in stasis disease. NLD ulcers, on the other hand, are deeper, have a punched-out appearance, and are associated with well-defined atrophic skin changes.

Comparison with Granuloma Annulare

Granuloma annulare (GA) is another condition that can mimic NLD. GA presents as flesh-colored or erythematous papules arranged in a ring (annular) pattern, often on the dorsal hands and feet. The generalized form of GA can involve the lower extremities. However, GA lacks the yellowish discoloration and prominent telangiectasias of NLD. GA lesions are usually asymptomatic and tend to resolve spontaneously over months to years. NLD is persistent and often progressive. Histologically, GA shows palisading granulomas with mucin deposition, whereas NLD features lipid deposition and more significant collagen degeneration.

Comparison with Sarcoidosis

Cutaneous sarcoidosis can present as violaceous, indurated plaques on the shins (lupus pernio or plaque sarcoidosis). These plaques may have a yellowish hue when compressed, but they typically do not show the waxy, atrophic center of NLD. Sarcoidosis is often accompanied by pulmonary, ocular, or lymph node involvement. Biopsy shows non-caseating granulomas without the necrobiosis and lipid deposits seen in NLD. Laboratory findings such as elevated angiotensin-converting enzyme (ACE) levels or hypercalcemia may point to sarcoidosis.

Comparison with Morphea (Localized Scleroderma)

Morphea presents as circumscribed, indurated, hyperpigmented or hypopigmented plaques that may have a lilac border. While both conditions cause skin thickening, morphea is firmer (“hidebound”) and may involve deeper tissue (subcutaneous fat, fascia). The surface is usually smooth but not waxy or shiny like NLD. Morphea rarely ulcerates, and it is not associated with diabetes. Histology shows a thickened dermis with collagen bundles and loss of adnexal structures, but no granulomas or lipid deposition.

Comparison with Pretibial Myxedema

Pretibial myxedema (dermopathy of Graves’ disease) appears as bilateral, asymmetric, nonpitting, waxy, and sometimes erythematous plaques on the shins. The skin may have an orange-peel texture. It is associated with hyperthyroidism (especially Graves’ disease) and often accompanied by exophthalmos and acropachy. In contrast, NLD is associated with diabetes, not thyroid disease. The plaques of myxedema are more edematous and have a faint purple hue. Biopsy reveals mucin deposition in the dermis, not necrobiosis.

Diagnostic Approach

A thorough clinical evaluation is the cornerstone of diagnosis. Key steps include:

  • Medical history: Assess for diabetes, duration of diabetes, glycemic control (HbA1c), and family history. Inquire about previous skin biopsies or treatments.
  • Physical examination: Examine the entire skin surface, noting the shape, color, texture, and distribution of lesions. Look for telangiectasias, atrophy, and ulceration. Check for signs of diabetic complications (peripheral neuropathy, retinopathy, nephropathy).
  • Skin biopsy: A punch biopsy from the active border (including the edge of a plaque) is essential for confirmation. Histopathology shows a palisading granulomatous dermatitis with collagen degeneration, lipid deposition, and thickened blood vessel walls. Gomori methenamine silver stain may highlight basement membrane thickening.
  • Laboratory tests: Fasting blood glucose, HbA1c, and oral glucose tolerance test if diabetes is not known. In nondiabetic patients, repeat testing annually as NLD can precede diabetes diagnosis by years. Thyroid function tests and ACE level may be helpful to exclude alternative diagnoses.
  • Imaging: Rarely needed, but if sarcoidosis or morphea is suspected, chest X-ray and autoantibody panels can be considered.

Treatment and Management

Management of NLD is challenging because spontaneous resolution is uncommon, and many treatments have limited evidence. The primary goals are to prevent ulceration, control associated diabetes, and improve cosmetic appearance.

Glycemic Control

Optimizing blood glucose levels is the most important intervention. Tight glycemic control may slow progression and reduce the risk of new lesions, although existing plaques rarely regress. Insulin pump therapy or continuous glucose monitoring can help achieve target HbA1c below 7% (for most adults). Referral to an endocrinologist is recommended for diabetic patients with NLD.

Topical and Intralesional Therapies

High-potency topical corticosteroids (e.g., clobetasol propionate) may reduce inflammation and border activity, but they do not reverse atrophy and can cause skin thinning with prolonged use. Intralesional corticosteroid injections (triamcinolone acetonide) are often used for active borders, with caution to avoid atrophy. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) are an option for nonulcerated plaques, and some case series report benefit. Topical vitamin D analogs (calcipotriol) have been tried with mixed results.

Systemic Treatments

For extensive or progressive disease, systemic therapies may be considered. Low-dose oral corticosteroids (e.g., prednisone 15–30 mg/day) can suppress inflammation but are not suitable for long-term use due to side effects and risk of worsening diabetes. Hydroxychloroquine (200–400 mg/day) has shown modest benefit in some patients, presumably via immunomodulation. Other options include mycophenolate mofetil, cyclosporine, infliximab, and etanercept, but evidence is limited to case reports. Pentoxifylline (400 mg three times daily) improves microcirculation and has been reported to reduce ulcer size.

Treatment of Ulcers

Ulcerated NLD requires aggressive wound care. Standard management includes debridement, moist dressings, and infection control. Topical growth factors (e.g., platelet-derived growth factor) or bioengineered skin substitutes (Apligraf) may be used for refractory cases. Negative pressure wound therapy can accelerate granulation. Compression therapy is avoided unless venous insufficiency is also present, as it may reduce perfusion in NLD ulcers. Systemic antibiotics are indicated for cellulitis.

Other Therapies

Photodynamic therapy, pulsed dye laser (for telangiectasias and erythema), and excimer laser (308 nm) have been used with variable success. Surgical excision or grafting is generally discouraged because new lesions often appear at donor sites and at the wound margins (Koebner phenomenon). However, excision may be considered for isolated, nonhealing ulcers.

Complications and Prognosis

The most significant complication is chronic, nonhealing ulcers that can become infected and lead to cellulitis, osteomyelitis, or even sepsis. Squamous cell carcinoma arising in chronic NLD ulcers has been reported but is rare. NLD itself does not increase mortality, but the associated diabetes and its comorbidities determine overall prognosis. Patients with NLD should be monitored regularly for diabetic complications, as NLD is a marker of microvascular disease.

The course of NLD is unpredictable. Plaques may remain stable for years, slowly enlarge, or occasionally regress spontaneously (less than 20%). Ulceration significantly worsens quality of life. There is no known cure, and treatment is mainly supportive.

When to Seek Medical Advice

Individuals with diabetes who notice any persistent, shiny, yellowish patches on their legs should consult a dermatologist or their primary care provider. Early referral allows for biopsy and confirmation of diagnosis, which can prevent unnecessary treatments for misdiagnosed conditions. Any sudden change in a plaque, such as pain, bleeding, or rapid enlargement, requires immediate evaluation. For patients without known diabetes, NLD may be the presenting sign of glucose intolerance; therefore, metabolic screening is warranted.

Key points for patient education: Avoid trauma to shins (use protective padding), keep skin well-moisturized, and perform daily self-examinations for ulcers. Regular follow-up with both a dermatologist and an endocrinologist is essential.

Conclusion

Necrobiosis lipoidica diabeticorum, or jelly diabetes, is a distinctive but often overlooked cutaneous manifestation of diabetes. Its hallmark waxy, yellowish plaques with telangiectasias and potential for ulceration set it apart from eczema, psoriasis, stasis dermatitis, granuloma annulare, and other mimickers. Diagnosis rests on clinical suspicion supported by histopathology and metabolic evaluation. While no definitive therapy exists, optimal glycemic control, judicious use of anti-inflammatory agents, and meticulous wound care can mitigate complications. Clinicians should maintain a high index of suspicion when evaluating persistent shin lesions, as early recognition leads to better outcomes and reinforces the importance of comprehensive diabetes management.

For further reading, see the American Diabetes Association guidelines on diabetic skin complications and dermatology textbooks such as Fitzpatrick's Dermatology in General Medicine.